March 30, 2020 News by Marta Figueiredo, PhD CHMP Favors Zeposia (Ozanimod) as Oral Treatment for Active RRMS in EU TheĀ Committee for Medicinal Products for Human UseĀ (CHMP) has recommended Zeposia (ozanimod) oral capsules to be approved in the European Union (EU) to treat adults with active relapsing-remitting multiple sclerosis (RRMS). Opinions released by CHMP, an arm of theĀ European Medicines AgencyĀ (EMA), are generally accepted by the European Commission,…
March 26, 2020 News by Marta Figueiredo, PhD FDA Approves Zeposia (Ozanimod), Oral Therapy for All with Relapsing MS The U.S. Food and Drug Administration (FDA) has approved ZeposiaĀ (ozanimod) oral capsules to treat adults with relapsing forms ofĀ multiple sclerosisĀ (MS), includingĀ relapsing-remitting MS (RRMS), Ā active secondary progressive MS (SPMS), and clinically isolated syndromeĀ (CIS). Due to the COVID-19 pandemic, however, when it will arrive in clinics…